BCG based vaccine compositions and methods of use thereof
AssigneeThe Johns Hopkins University
InventorsAlok Singh, Peter Um, Keira Cohen, William Bishai, Rulin Wang, Srinivasan Yegnasubramanian, Trinity J. Bivalacqua
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a BCG based therapeutic agent using a BCG strain that overexpresses the STING agonist, c-di-AMP. This BCG strain, called BCG-disA-OE, enhances the elevated trained immunity of macrophages and promotes early anti-viral Type I interferon responses in a subject, providing protection against viral infections such as primary respiratory infections and SARS-CoV-2 infection.
Claims14
A method of preventing, ameliorating or treating a viral infection in a subject comprising administering to the subject a recombinant bacille Calmette-Guerin (BCG) bacterial strain of Mycobacterium bovis comprising an exogenous nucleic acid construct comprising:
- a mycobacterial promoter and a disA gene,
- wherein the disA gene is a Mycobacterium tuberculosis gene, and
- wherein the viral infection is a primary respiratory infection thereby treating the infection.
Dependencies are inferred from the claim text.